Skip to main content
. 2018 Jan 19;115(6):E1147–E1156. doi: 10.1073/pnas.1717802115

Fig. 3.

Fig. 3.

Characterization of the stromal component of Saa3-null tumors. (A, Left) Masson’s trichrome and Sirius Red staining of collagen in Saa3-competent (WT) and Saa3-null (KO) tumors. (Scale bars, 50 μm.) (Right) Quantitative analysis of Masson’s trichrome-stained sections of Saa3-competent (WT) and Saa3-null (KO) tumors (n = 4). (B, Left) Representative images of F4/80 and CD31 immunostaining in Saa3-competent (WT) and Saa3-null (KO) tumors. (Scale bars, 50 μm.) (Right) Quantitative analysis of F4/80- and CD31-stained sections of Saa3-competent (WT) and Saa3-null (KO) tumors (n = 5). (C, Left) FACS analysis of fresh Saa3-competent (WT) and Saa3-null (KO) tumor samples with anti-F4/80 and anti-CD11b antibodies. (Center) FACS analysis of F4/80+/CD11b+ double-positive macrophages with anti-CD11c and anti-CD206 antibodies. The percentage of M1 (CD11chigh/CD206low) (blue square) and M2 (CD11clow/CD206high) (red square) macrophage populations is indicated for each tumor type. (Right) Quantitative analysis of M1 and M2 macrophages in Saa3-competent (WT) and Saa3-null (KO) tumors (n = 2). (D, Left) Micro-ultrasound images of Saa3-competent (WT) and Saa3-null (KO) tumors after injection of contrast agent. (Right) Quantitative analysis of vessel density in Saa3-competent (WT) and Saa3-null KO) tumors (n = 5). *P < 0.05; **P < 0.001; ***P < 0.001.